Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India.
Metrics to compare | SPRL | Peers Peers - average of corresponding metrics from companies closely matching SPRL: SMSPHARMA, SHILPAMED, ALIVUS, MOREPENLAB, INDSWFTLTD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRLPeersSector |
---|---|---|---|---|
P/E Ratio | 30.0x | 23.7x | −0.6x | |
PEG Ratio | 0.94 | 0.08 | 0.00 | |
Price/Book | 5.4x | 2.6x | 2.6x | |
Price / LTM Sales | 7.8x | 1.8x | 3.3x | |
Upside (Analyst Target) | 20.7% | 18.4% | 39.0% | |
Fair Value Upside | Unlock | 4.3% | 4.9% | Unlock |